nonpharmaceutical

"[The CDC] examined 43 cities and found that so-called nonpharmaceutical interventions -- steps such as isolating patients and school closings -- were remarkably successful in tamping down the outbreak."

Fanatic Cook 2009

"[The CDC] examined 43 cities and found that so-called nonpharmaceutical interventions -- steps such as isolating patients and school closings -- were remarkably successful in tamping down the outbreak."

Fanatic Cook 2009

The strategy has run counter to those pursued by rivals, including Pfizer, which have gotten bigger and diversified into nonpharmaceutical areas.

Bristol-Myers Profit Falls on Prior-Year Asset Gain Peter Loftus 2011

Pfizer is in the midst of exploring the potential divestiture of nonpharmaceutical assets, including its animal-health and nutrition units.

Pfizer Profit Rises 5.5% Peter Loftus 2011

CEO Mr. Frazier hinted Friday that Merck wasn't likely to divest itself of some of the nonpharmaceutical businesses Merck acquired in the Schering deal.

Merck's Profit Soars on Lower Charges Peter Loftus 2011

In recent years, Bristol has pursued a strategy of shedding its nonpharmaceutical assets, such as baby formula Enfamil, and using proceeds to make modest-sized acquisitions to bolster its drug portfolio.

Bristol-Myers Profit Falls on Prior-Year Asset Gain Peter Loftus 2011

When she and I discussed my research on the uses of nonpharmaceutical interventions (NPIs) for pandemic mitigation, I clearly stated that hand-washing and social distancing alone would not protect the majority of Americans from a severe influenza pandemic.

Letters to the Editor 2009

He was known during a nearly four-year tenure as chief executive of Bristol-Myers for shedding the company's nonpharmaceutical assets while many competitors diversified and got bigger.

Mead Johnson Chief in Buy Mode Kathy Shwiff 2011

When she and I discussed my research on the uses of nonpharmaceutical interventions (NPIs) for pandemic mitigation, I clearly stated that hand-washing and social distancing alone would not protect the majority of Americans from a severe influenza pandemic.

Letters to the Editor 2009

Bristol's research-and-development victories followed a shift in strategy several years ago, when the company began shedding nonpharmaceutical assets and cutting costs.

Bristol-Myers Net Rises 76% on Lower Taxes Peter Loftus 2012